Die erste Leitlinie der European Society of Cardiology (ESC) zum Management der Myokarditis und Perikarditis führt das inflammatorische myoperikardiale Syndrom (IMPS) als übergeordnete Erkrankung für das gesamte Spektrum entzündlicher myokardialer und perikardialer Erkrankungen ein. Sie betont gemeinsame Ätiologien, klinische Überlappungen und die Notwendigkeit erhöhter Aufmerksamkeit für Risikokonstellationen („red flags“). Ein zentrales Novum ist der symptombasierte Algorithmus (Thoraxschmerz, Arrhythmie, Herzinsuffizienz) mit klaren diagnostischen und therapeutischen Pfaden. Die multimodale, primär nicht invasive Diagnostik, insbesondere mittels kardiovaskulärer Magnetresonanztomographie, ermöglicht eine definitive Myokarditisdiagnose. Die Endomyokardbiopsie sollte bei Hochrisikokonstellationen, wie z. B. bei instabiler Kreislaufsituation, oder bei Verdacht auf spezifische Myokarderkrankungen mit schnellem Therapiebedarf wie der Riesenzellmyokarditis angewendet werden. Genetische, autoimmunologische und autoinflammatorische Mechanismen werden stärker berücksichtigt inklusive selektiver genetischer Testung. Therapeutisch werden eine risikoadaptierte, personalisierte Strategie von antiinflammatorischer Behandlung über Herzinsuffizienz- und Device-Therapie sowie eine individualisierte Sport- und Arbeitskarenz angeboten. Für die rezidivierende Perikarditis werden Anti-Interleukin-1-Therapien integriert. Multidisziplinäre Betreuung ist bei komplizierten Verläufen ein zentraler Bestandteil des Managements.
Introduction Tricuspid regurgitation (TR) is frequently associated with severe venous congestion, increasingly recognized as a key factor in the development of cardiorenal syndrome. While transcatheter tricuspid valve intervention (TTVI) has shown to be effective in TR reduction, their impact on visceral venous congestion remains unknown. The aim of our study was to investigate visceral venous congestion in patients with severe TR undergoing TTVI. Methods We prospectively enrolled 30 patients undergoing TTVI for severe TR. Renal venous blood flow was assessed by Doppler ultrasound examination at baseline and 1 to 3 months after the procedure. A 5-grade rating scale was developed to categorize venous flow from continuous (Grade I degrees) through discontinuous to a pendulous venous flow (Grade V degrees) within the kidneys. Results Transcatheter edge-to-edge repair (TEER, n = 24) was performed in 24 patients; 6 patients underwent heterotopic caval valve implantation. At baseline, severe renal congestion was present in most participants, with 20 patients showing venous flow profiles IV or V. Venous flow profiles strongly correlated with invasively measured right atrial mean pressure and V wave (p < 0.01). At follow-up, venous renal blood flow profiles improved significantly (p = 0.003), reducing patients with profiles IV or V from 20 to 9. Portal vein flow showed comparable decongestive changes. In TEER patients, reduction of TR >= 2 grades was associated with improved renal vein profile at follow-up (p = 0.002). Conclusion Successful TTVI leads to visceral decongestion. Renal venous flow currently represents a physiological marker of congestion that may complement conventional echocardiographic parameters; its role in guiding patient selection or timing of intervention remains to be determined in larger studies.
3561 Background: The use of overall response rate (ORR) and progression-free survival (PFS) as surrogacy of overall survival (OS) has limitations in mCRC. Change in tumor load (ΔTL; tumor burden at progressive disease [PD] vs baseline) at treatment failure may reflect tumor aggressiveness and resistance biology. We evaluated the prognostic value of ΔTL in mCRC using IPD from twelve randomized first-line trials. Methods: IPD from ATEZOTRIBE, FIRE3, FIRE4, FIRE4.5, MACBETH, ML22011, MOMA, PANAMA, TRIBE, TRIBE2, TRIPLETE, and VALENTINO were pooled. ΔTL was defined as the ratio of the sum of longest target lesion diameters at PD vs baseline, per RECIST. Primary endpoint was OS; secondary endpoints included post-progression survival (PPS). Estimated marginal means were controlled for treatment type. Associations between ΔTL and outcomes were assessed using Cox models adjusted for prespecified baseline tumor burden and clinical covariates (ECOG, age, sex, sidedness, RAS/BRAF status, metastatic patterns, previous therapies). Incremental prognostic value beyond early tumor shrinkage (ETS) and depth of response (DpR) was assessed using likelihood ratio testing. Effect modification by treatment regimen was evaluated using ΔTL × treatment interaction terms for EGFR- vs VEGF-based therapy and for triplet vs doublet-chemotherapy across trials. Results: A total of 4852 patients evaluable for ΔTL were included. Mean ΔTL was 0.63 (SD 0.45) and significantly lower in patients receiving EGFR- vs VEGF-based therapy (0.58 vs 0.66, p<0.001) and triplet vs doublet chemotherapy (0.57 vs 0.67, p<0.001). Lower ΔTL (lower tumor load at PD vs baseline) was associated with better OS (HR 0.58 [95% CI 0.55–0.61], p<0.001) and PPS (HR 0.65 [0.61–0.69], p<0.001) after adjustment for baseline tumor burden and clinical covariates. For OS, ΔTL added prognostic information beyond ETS (likelihood ratio χ² = 282.13, p<0.001) and DpR (likelihood ratio χ² = 121.91, p<0.001). Lower ΔTL was associated with improved OS in patients receiving EGFR- (n = 1609; HR 0.62 [0.58–0.67], p<0.001) and VEGF-based therapy (n = 1916; HR 0.39 [0.35–0.43], p<0.001); doublet (n = 2177; HR 0.61 [0.57–0.65], p<0.001) and triplet (n = 1348; HR 0.34 [0.30–0.38], p<0.001) chemotherapy, with significant ΔTL × treatment interaction (VEGF vs EGFR: HR 0.50 [0.46–0.54], p<0.001; triplet vs doublet: HR 0.60 [0.54–0.66], p<0.001) after adjustment for treatment regimen, RAS/BRAF status and other clinical covariates. Conclusions: TL appears to be a strong, independent prognostic marker for OS and PPS in mCRC. ΔTL seems to vary by biologic and chemotherapy intensity, indicating it captures differential treatment effect/resistance not captured by ORR or PFS. Prospective validation as an early, treatment-sensitive prognostic endpoint is warranted.